Birchview Capital, LP
Filing Date
Global Rank
#6,329
/ 8,794
▼ 214
· as of Jun 2026
Top Industry
Biotechnology
43.0%
Period ended 3 months ago
Filed Aug 14, 2026 · 52d
26 quarters · since Mar 2020
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
71 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
25.4%
+8.4 pts
Top 5
46.8%
+6.2 pts
Top 10
60.3%
+4.8 pts
HHI
863
Diversified+302
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 63.1% | $133,735,320 |
| Technology | 32.6% | $69,013,035 |
| Energy | 3.5% | $7,500,567 |
| Basic Materials | 0.5% | $1,134,221 |
| Financial Services | 0.3% | $628,400 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
17 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | +209,133 | 1,675,000 | $3,668,250 | |
| KLAC | Kla Corp | +158,588 | 178,471 | $53,846,485 | |
| GRCE | Grace Therapeutics, Inc. | +70,000 | 120,000 | $272,400 | |
| NKTR | Nektar Therapeutics | +50,000 | 81,000 | $5,654,610 | |
| SLDB | Solid Biosciences Inc. | +40,216 | 666,196 | $6,655,298 | |
| ZBIO | Zenas BioPharma, Inc. | +23,601 | 93,601 | $2,375,593 | |
| HALO | Halozyme Therapeutics, Inc. | +23,151 | 33,251 | $2,602,555 | |
| VERA | Vera Therapeutics, Inc. | +13,758 | 57,758 | $2,478,395 | |
| CORT | Corcept Therapeutics Inc | +10,000 | 57,200 | $4,973,540 | |
| BIIB | Biogen Inc. | +4,000 | 9,000 | $1,944,540 | |
| VYGR | Voyager Therapeutics, Inc. | +229 | 75,147 | $263,014 | |
| FHTX | Foghorn Therapeutics Inc. | +207 | 281,937 | $1,375,852 | |
| CSTL | Castle Biosciences Inc | +84 | 12,984 | $309,668 | |
| BBIO | BridgeBio Pharma, Inc. | +53 | 8,741 | $651,029 | |
| XENE | Xenon Pharmaceuticals Inc. | +32 | 21,032 | $1,269,491 | |
| PTGX | Protagonist Therapeutics, Inc | +18 | 35,018 | $4,292,506 | |
| UTHR | UNITED THERAPEUTICS Corp | +6 | 4,506 | $2,441,485 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
21 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | −345,000 | 30,000 | $424,500 | |
| OCUL | Ocular Therapeutix, Inc | −299,345 | 20,655 | $202,832 | |
| PACB | Pacific Biosciences Of California, Inc. | −150,000 | 1,350,000 | $2,268,000 | |
| BCYC | Bicycle Therapeutics PLC | −149,983 | 313,616 | $1,329,731 | |
| PHAT | Phathom Pharmaceuticals, Inc. | −140,000 | 55,000 | $596,750 | |
| LPCN | Lipocine Inc. | −95,074 | 16,712 | $42,782 | |
| GPCR | Structure Therapeutics Inc. | −76,000 | 24,000 | $1,288,080 | |
| NTLA | Intellia Therapeutics, Inc. | −59,500 | 385,900 | $6,529,428 | |
| QURE | uniQure N.V. | −50,000 | 50,697 | $2,335,103 | |
| LUNG | Pulmonx Corp | −49,678 | 200,543 | $260,705 | |
| KPTI | Karyopharm Therapeutics Inc. | −41,000 | 42,952 | $419,641 | |
| STOK | Stoke Therapeutics, Inc. | −31,890 | 178,110 | $5,827,759 | |
| OLMA | Olema Pharmaceuticals, Inc. | −20,000 | 199,000 | $2,489,490 | |
| CADL | Candel Therapeutics, Inc. | −12,244 | 47,756 | $491,886 | |
| BMY | Bristol Myers Squibb Co | −9,025 | 297,243 | $17,127,141 | |
| RLMD | Relmada Therapeutics, Inc. | −1,287 | 408,100 | $2,824,052 | |
| LRCX | Lam Research Corp | −1,000 | 35,000 | $15,166,550 | |
| DCGO | DocGo Inc. | −511 | 39,062 | $20,155 | |
| TVTX | Travere Therapeutics, Inc. | −200 | 29,000 | $1,647,490 | |
| CLDX | Celldex Therapeutics, Inc. | −195 | 69,900 | $2,600,979 | |
| FCX | Freeport-Mcmoran Inc | −5 | 18,035 | $1,134,221 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
14 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ABVX | Abivax S.A. | 17,000 | $2,265,420 | |
| VIR | Vir Biotechnology, Inc. | 220,000 | $2,241,800 | |
| BIOA | BioAge Labs, Inc. | 69,000 | $1,691,190 | |
| NVO | Novo Nordisk A S | 24,000 | $1,150,560 | |
| ADAG | Adagene Inc. | 240,000 | $1,008,000 | |
| DFTX | Definium Therapeutics, Inc. | 20,000 | $940,800 | |
| SLN | Silence Therapeutics plc | 71,218 | $781,973 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 48,505 | $645,116 | |
| URGN | UroGen Pharma Ltd. | 16,487 | $606,721 | |
| CAMP | Camp4 Therapeutics Corp | 120,000 | $524,400 | |
| SVRA | Savara Inc | 80,000 | $492,800 | |
| ALT | Altimmune, Inc. | 152,681 | $464,150 | |
| CAPR | Capricor Therapeutics, Inc. | 14,352 | $345,596 | |
| IVVD | Invivyd, Inc. | 342,275 | $298,463 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
15 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| NVCR | NovoCure Ltd | 202,330 | $2,205,397 | |
| ENGN | enGene Therapeutics Inc. | 250,000 | $1,702,500 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 62,000 | $1,298,900 | |
| VSTM | Verastem, Inc. | 150,000 | $795,000 | |
| — | 9,000 | $757,530 | ||
| IDYA | IDEAYA Biosciences, Inc. | 16,860 | $561,775 | |
| RCUS | Arcus Biosciences, Inc. | 25,889 | $559,202 | |
| RGNX | REGENXBIO Inc. | 66,270 | $555,342 | |
| RCKT | Rocket Pharmaceuticals, Inc. | 127,025 | $454,749 | |
| VRDN | Viridian Therapeutics, Inc.\DE | 20,100 | $393,156 | |
| OM | Outset Medical, Inc. | 98,882 | $379,706 | |
| PHR | Phreesia, Inc. | 14,300 | $119,834 | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 17,503 | $40,957 | |
| — | 14,000 | $0 | ||
| — | 57,000 | $0 | ||
| No positions match the current search. | ||||
71 tracked positions ·
$212,011,543 total
· filing declares
73 positions · $213,828,198
· as of Jun 30, 2026
Showing 1–50
of 71 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KLAC |
Kla Corp
Technology
|
Added | 178,471 | $53,846,485 | 25.40% | |
| BMY |
Bristol Myers Squibb Co
Healthcare
|
Reduced | 297,243 | $17,127,141 | 8.08% | |
| LRCX |
Lam Research Corp
Technology
|
Reduced | 35,000 | $15,166,550 | 7.15% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
Added | 666,196 | $6,655,298 | 3.14% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Reduced | 385,900 | $6,529,428 | 3.08% | |
| BDSX |
Biodesix Inc
Healthcare
|
Held | 286,804 | $6,467,430 | 3.05% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Reduced | 178,110 | $5,827,759 | 2.75% | |
| OVV |
Ovintiv Inc.
Energy
|
Held | 107,500 | $5,659,875 | 2.67% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Added | 81,000 | $5,654,610 | 2.67% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
Added | 57,200 | $4,973,540 | 2.35% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
Held | 27,190 | $4,582,602 | 2.16% | |
| PRTA |
Prothena Corp Public Ltd Co
Healthcare
|
Held | 449,019 | $4,395,896 | 2.07% | |
| ACAD |
Acadia Pharmaceuticals Inc
Healthcare
|
Held | 171,000 | $4,326,300 | 2.04% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Added | 35,018 | $4,292,506 | 2.02% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
Added | 1,675,000 | $3,668,250 | 1.73% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Reduced | 408,100 | $2,824,052 | 1.33% | |
| ALKS |
Alkermes plc.
Healthcare
|
Held | 50,000 | $2,620,000 | 1.24% | |
| HALO |
Halozyme Therapeutics, Inc.
Healthcare
|
Added | 33,251 | $2,602,555 | 1.23% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 69,900 | $2,600,979 | 1.23% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Held | 30,000 | $2,555,700 | 1.21% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Reduced | 199,000 | $2,489,490 | 1.17% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
Added | 57,758 | $2,478,395 | 1.17% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
Added | 4,506 | $2,441,485 | 1.15% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Added | 93,601 | $2,375,593 | 1.12% | |
| QURE |
uniQure N.V.
Healthcare
|
Reduced | 50,697 | $2,335,103 | 1.10% | |
| PACB |
Pacific Biosciences Of California, Inc.
Healthcare
|
Reduced | 1,350,000 | $2,268,000 | 1.07% | |
| ABVX |
Abivax S.A.
Healthcare
|
NEW | 17,000 | $2,265,420 | 1.07% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
NEW | 220,000 | $2,241,800 | 1.06% | |
| BIIB |
Biogen Inc.
Healthcare
|
Added | 9,000 | $1,944,540 | 0.92% | |
| EQT |
EQT Corp
Energy
|
Held | 34,619 | $1,840,692 | 0.87% | |
| BIOA |
BioAge Labs, Inc.
Healthcare
|
NEW | 69,000 | $1,691,190 | 0.80% | |
| TVTX |
Travere Therapeutics, Inc.
Healthcare
|
Reduced | 29,000 | $1,647,490 | 0.78% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Held | 6,000 | $1,468,620 | 0.69% | |
| FHTX |
Foghorn Therapeutics Inc.
Healthcare
|
Added | 281,937 | $1,375,852 | 0.65% | |
| BCYC |
Bicycle Therapeutics PLC
Healthcare
|
Reduced | 313,616 | $1,329,731 | 0.63% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Reduced | 24,000 | $1,288,080 | 0.61% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Added | 21,032 | $1,269,491 | 0.60% | |
| NVO |
Novo Nordisk A S
Healthcare
|
NEW | 24,000 | $1,150,560 | 0.54% | |
| FCX |
Freeport-Mcmoran Inc
Basic Materials
|
Reduced | 18,035 | $1,134,221 | 0.53% | |
| IMNM |
Immunome Inc.
Healthcare
|
Held | 50,000 | $1,059,500 | 0.50% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Held | 29,847 | $1,032,109 | 0.49% | |
| HROW |
Harrow, Inc.
Healthcare
|
Held | 24,000 | $1,019,280 | 0.48% | |
| ADAG |
Adagene Inc.
Healthcare
|
NEW | 240,000 | $1,008,000 | 0.48% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 20,000 | $940,800 | 0.44% | |
| SLN |
Silence Therapeutics plc
Healthcare
|
NEW | 71,218 | $781,973 | 0.37% | |
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Added | 8,741 | $651,029 | 0.31% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
NEW | 48,505 | $645,116 | 0.30% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
NEW | 16,487 | $606,721 | 0.29% | |
| PHAT |
Phathom Pharmaceuticals, Inc.
Healthcare
|
Reduced | 55,000 | $596,750 | 0.28% | |
| CAMP |
Camp4 Therapeutics Corp
Healthcare
|
NEW | 120,000 | $524,400 | 0.25% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.